CN106420829A - 五谷虫制品用于制备治疗胶质细胞瘤的药品、保健品或食品中的应用 - Google Patents
五谷虫制品用于制备治疗胶质细胞瘤的药品、保健品或食品中的应用 Download PDFInfo
- Publication number
- CN106420829A CN106420829A CN201610811515.9A CN201610811515A CN106420829A CN 106420829 A CN106420829 A CN 106420829A CN 201610811515 A CN201610811515 A CN 201610811515A CN 106420829 A CN106420829 A CN 106420829A
- Authority
- CN
- China
- Prior art keywords
- product
- fab
- maggot
- chrysomyiame gacephala
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 230000036541 health Effects 0.000 title claims abstract description 9
- 235000013305 food Nutrition 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 10
- 208000032612 Glial tumor Diseases 0.000 claims description 10
- 206010018338 Glioma Diseases 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 241000522620 Scorpio Species 0.000 claims description 4
- 239000009490 scorpio Substances 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 229920001661 Chitosan Polymers 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 2
- 229930195729 fatty acid Natural products 0.000 abstract description 2
- 239000000194 fatty acid Substances 0.000 abstract description 2
- 150000004665 fatty acids Chemical class 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 abstract 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 239000003925 fat Substances 0.000 abstract 1
- 230000000452 restraining effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 18
- 238000009395 breeding Methods 0.000 description 9
- 230000001488 breeding effect Effects 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 210000003128 head Anatomy 0.000 description 6
- 241000202815 Chrysomya megacephala Species 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000002917 insecticide Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000257161 Calliphoridae Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000255925 Diptera Species 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000010981 turquoise Substances 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 241000134068 Mesostigma Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241000270934 Rana catesbeiana Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000000729 Schizencephaly Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002579 anti-swelling effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004086 maxillary sinus Anatomy 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Insects & Arthropods (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种肿瘤治疗领域，尤其涉及五谷虫制品用于制备治疗胶质细胞瘤的药品、保健品或食品中的应用。本发明的五谷虫制品为一种天然的产品，五谷虫制品有效成分是五谷虫全虫，现代医学研究证明：五谷虫中含蛋白质、脂肪、几丁聚糖、含抗菌肽以及18种氨基酸。本发明的五谷虫干粉中包括了五谷虫全虫的所有有效成分，五谷虫提取物主要是以脂肪酸和/或蛋白质、多肽、氨基酸等。经研究发现，五谷虫制品可以有效抑制胶质细胞瘤生长，且五谷虫制品不具有临床上常用的化疗药的耐药及其毒副作用。
Description
技术领域
本发明涉及一种肿瘤治疗领域，尤其涉及五谷虫制品用于制备治疗胶质细胞瘤的药品、保健品或食品中的应用。
背景技术
五谷虫为丽蝇科(Calliphoridae)昆虫大头金蝇(ChrysomyiamegacephalaFab.)或其他近缘昆虫的干燥幼虫体，在古代医书中就有记载，用于治疗小儿疳积、脓包疮。
目前记载五谷虫具有以下药理作用：1.平喘作用，五谷虫所含的总氨基酸是平喘的有效成分；2.对肠平滑的作用，五谷虫乙醇提取物和五谷虫总氨基酸粗提取物对组胺所致离体家兔和豚鼠的回肠平滑肌痉挛均有明显的争痉作用；3.毒性，五谷虫的毒性很小。
中国发明专利申请(申请号CN200510060277.4申请日2005.08.04)一种具有抗肿瘤生物活性蝇蛆的养殖方法。养殖的蝇蛆经过国家新药筛选中心几年来多次检测有对肝癌、乳腺癌、卵巢癌、宫颈癌、肺癌、胃癌、等肿瘤细胞生长有很强的抑制率，其抗肿瘤生物活性都在75％～97％。
中国发明专利申请(申请号CN200710067951.0申请日2007.04.10)公开了一类抗肿瘤化合物，该组份从外源物质诱导的蝇蛆中提取、分离获得，具有抑制人原髓细胞白血病HL－60和人肺腺癌A549细胞增殖生长的作用。
中国发明专利申请(申请号CN201310223817.0申请日2013.06.06)公开了一种五谷虫抗肿瘤新用途，通过五谷虫抑制小鼠肿瘤重量的作用来表现，五谷虫能抑制肿瘤细胞的生长，对肿瘤细胞具有杀伤作用，能够在制备抗肿瘤药物或保健品中应用，具体公开了小鼠肉瘤S180的生长抑制。
肺癌是世界上最常见的恶性肿瘤之一,已成为我国城市人口恶性肿瘤死亡原因的第1位。非小细胞型肺癌包括鳞状细胞癌(鳞癌)、腺癌、大细胞癌，与小细胞癌相比其癌细胞生长分裂较慢,扩散转移相对较晚。胶质细胞瘤约占所有肺癌的80％，约75％的患者发现时已处于中晚期，5年生存率很低。
发明内容
本发明的第一个目的是提供五谷虫制品用于制备治疗胶质细胞瘤的药品中的应用。
本发明的第二个目的是提供五谷虫制品用于制备抑制胶质细胞瘤的保健品中的应用。
本发明的第二个目的是提供五谷虫制品用于制备抑制胶质细胞瘤的食品中的应用。
作为优选，上述的五谷虫制品为五谷虫干粉和\或五谷虫提取物以及五谷虫干粉和\或五谷虫提取物制备的制剂。
作为再优选，所述的制剂为胶囊剂、片剂、丸剂、散剂、复方颗粒剂、保健酒、蛋白粉、口服液或冻干粉。
作为优选，上述的五谷虫提取物包括五谷虫全虫或五谷虫干粉的水提取物和有机溶剂提取物中的一种或多种。
作为再优选，所述的有机溶剂提取物中的有机溶剂包括乙醇、石油醚或己烷中的一种或多种。
本发明的五谷虫制品为一种天然的产品，五谷虫制品有效成分是五谷虫全虫，现代医学研究证明：五谷虫中含蛋白质、脂肪、几丁聚糖、含抗菌肽以及18种氨基酸。本发明的五谷虫干粉中包括了五谷虫全虫的所有有效成分，五谷虫提取物主要是以脂肪酸和/或蛋白质、多肽、氨基酸等。经研究发现，五谷虫制品可以有效抑制胶质细胞瘤生长，且五谷虫制品不具有临床上常用的化疗药的耐药及其毒副作用。
具体实施方式
实施例1
1、种蝇选择
动物学鉴定：丽蝇科Calliphoridae昆虫大头金蝇Chrysomyia megacephala(Fab.)。成蝇体长8～11毫米，绿蓝色、头部宽，顶部黑色；复眼大，深红色，额中条褐红色，颜和颊部橙黄色，触角及小颚须褐色。胸、腹部绿蓝色，带有紫色光泽。第1腹节及第2，3腹节后缘黑色。雌蝇的额部及中条在中部处向外侧略为凸出。雄蝇复眼上部2/3有大形的小眼面，下方1/3则为小形的小眼面，二者界面清晰。前胸气门黑色，中胸气门浅褐色；有气门。腋瓣带棕色，上有小毛。幼虫成熟时黄白色，前端尖细，后端截平。体节14，头部1节，胸部3节，腹部10节，但通常只见8节。体表由小棘形成的环。后气门略高出表面，较扁于上方，气门环不完全；后气门间距不大于后气门的横径；第1气门裂垂直形；前气门具有10—13个指状突。
2、种蝇采集
(1)种蝇箱的制作：可以选用木质、玻璃、陶瓷制作，圆形或长方形均可，顶部留一个直径25厘米的口，并制作一个用透气的网状盖，以防种蝇逃逸。
(2)种蝇饲料配置：奶粉+红糖，1:1混合，加15％的水调和，放置于种蝇箱内。
(3)打开种蝇箱网状盖，置于28--38摄氏度，湿度小于65％的环境内。
让外界的大头金蝇进入箱内觅食，对不符合要求的蝇种进行分拣丢弃，并盖上网状盖，使其滞留于种蝇箱内觅食、产卵。
3、养殖硬件与养殖饲料
(1)蝇房建造：按养殖规模，可以选用砖石，玻璃、塑料、钢架结构材料，离地面2米左右的墙体上间隔1.5--2米设置通风窗，为防止其他苍蝇或昆虫进入，宜设有纱窗与外界隔离，在养殖箱上方一米制成可活动的通风管道，便于废气收集，防止异味散发污染环境，废气统一通过臭氧除臭装置处理后排出。为防止蝇种进入废气收集管道，宜在各进气口设置纱窗隔断。
(2)养殖箱制作：可以选用木质、陶瓷、水泥材料，制成长方形箱体，底部设置止水密封装置，箱体上方留一个直径30--40厘米的圆孔，即可。各养殖箱下方设有污水收集通道，统一进入污水池处理后排放。
(3)保温：为符合养殖产品的标准化要求，可以附设加温、降温设施。在炎热时季可在蝇房顶面设置防嗮遮阳设施。
(4)养殖饲料：猪内脏、淡水鱼、牛蛙、奶粉、蜂蜜。
4、养殖工艺步骤
(1)蝇种：采集的蝇种移植到提前一天放有淡水鱼的种蝇箱内，培养2天，待其在箱内产卵。
(2)收集蝇卵：待种蝇在蝇种箱内产卵，即可将蝇卵收集，转移到加有饲料的蝇房养殖箱内进行孵化、养殖，饲料和蝇卵的比例为每5克蝇卵，加入15公斤的饲料。
(3)孵化养殖：蝇卵孵化后，即可在养殖箱内获得所需的饲料，一般需要72小时，虫体长到长度1--1.2厘米，直径2.5--3毫米时。
(4)活性催化：在养殖箱内加入用200毫升预配的5％蔗糖(w/w)水溶液和1％的超氧化物歧化酶(LA-SOD)(酶系活力大于300万单位/克)500毫升，2小时后取出活体五谷虫，用清水反复冲洗干净，即刻放入—38摄氏度以下的冰柜内速冻。
(5)清洗干燥：低温速冻两天后，取出，在清水中融化，再仔细清洗，沥干水分，使用真空低温干燥设备干燥到水分含量低于10％。
试验例1
一、实验目的
应用AnnexinV-FITC/PI-FCM定量分析二氧化碳萃取物样品诱导U-118MG人星形胶质细胞瘤株细胞发生凋亡的现象和比例及时间周期。
二、主要实验仪器与材料，
1、材料
1.1.U-118MG人星形胶质细胞，购自中国科学院细胞库。
DMEM培养基(GIBCO,添加NaHCO3 1.5g/L)，90％；胎牛血清，10％。气相：空气，95％；二氧化碳，5％。温度：37摄氏度。
1.2药物与试剂抗肿瘤五谷虫二氧化碳萃取物，AnnexinV-FITC/PI凋亡试剂盒为南京凯基公司产品；RNA酶A，胰蛋白酶(GIBCO)。
2、主要仪器
BD流式细胞仪BD FACSCaliburTM
三、实验方法和步骤
1.药物处理萃取油脂压滤备用
3、数据与图像分析
在二维的FCM分析图上，细胞分为四个亚群：左下(LL)象限，Annexin V-FITC-/PI-为活细胞群(V)；右下(LR)象限，Annexin V-FITC+/PI-为凋亡细胞(AP)，此区细胞具有典型的凋亡细胞特征：包括细胞与核体积缩小，染色质浓缩致密，有新月体状核形成，细胞膜上的微绒毛消失；右上(UR)象限，AnnexinV-FITC+/PI+细胞已具有了坏死细胞的特征：细胞膜破裂，细胞器肿胀，胞质内空泡化，为继发性坏死细胞(N)；左上(UL)象限，AnnexinV-FITC-/PI+为培养操作过程中出现的机械损伤细胞(O)。
四、实验结果
表二氧化碳萃取物浓度和作用时间对诱导细胞凋亡的影像
注：V：左下(LL)象限，活细胞群所占百分比；AP：右下(LR)象限，凋亡细胞所占百分比；N：右上(UR)象限，继发性坏死细胞所占百分比；O：左上(UL)象限，机械损伤细胞所占百分比。
五：实验结果分析：
实验结果显示：该样品在72小时当药物浓度增加时到0.25mg，出现明显的凋亡现象，且在0.5，其凋亡细胞的比率显著增加。
试验例2
晋**，男，59岁，患者于2015年3月因右侧头部及右眼跳痛、四肢无力入在吉林省白求恩第一医院治疗，诊断为胶质母细胞瘤WHOⅥ级，右侧基底节及颞叶区见片状低及稍低混杂密度影，边界模糊，邻近侧脑室受压变小，右侧部分脑沟、脑裂显示不佳，左侧上颌窦见囊性低密度影，四肢肌力5级，无手术适应症，病人拒绝放化疗，于2015年3月25日开始服用抗肿瘤五谷虫，2016年4月复查，个人生活能自理，颞叶区片状阴影改善，边界基本清晰，与前片对比有缩小，尚在继续服用中。
试验例3
王**男，55岁，山东省莱芜市，2014年患者因发音吐字困难，在山东省立医院检查，颅脑MRI平扫+增强发现左额顶叶占位性病变，于2014年11月19日行切除术，病理诊断结果为胶质母细胞瘤，Ⅵ级，2015年7月复查发现，颅内有明显水肿，条索状不规则强化信号，边界模糊，大小3.5*1*1.9cm，视力模糊，吞咽困难，经人介绍，开始服用抗肿瘤五谷虫，服用3个月复查，精神状态明显好转，边界清晰，大小为3.0*0.8*1.2cm，比照2015年7月影像，显示有缩小，目前还在继续治疗中。
Claims (7)
1.五谷虫制品用于制备治疗胶质细胞瘤的药品中的应用。
2.五谷虫制品用于制备抑制胶质细胞瘤的保健品中的应用。
3.五谷虫制品用于制备抑制胶质细胞瘤的食品中的应用。
4.根据权利要求1~3任意一项权利要求所述的应用，其特征在于五谷虫制品为五谷虫干粉和\或五谷虫提取物以及五谷虫干粉和\或五谷虫提取物制备的制剂。
5.根据权利要求4所述的应用，其特征在于制剂为胶囊剂、片剂、丸剂、散剂、复方颗粒剂、保健酒、蛋白粉、口服液或冻干粉。
6.根据权利要求4所述的应用，其特征在于五谷虫提取物包括五谷虫全虫或五谷虫干粉的水提取物和有机溶剂提取物中的一种或多种。
7.根据权利要求6所述的应用，其特征在于有机溶剂提取物中的有机溶剂包括乙醇、石油醚或己烷中的一种或多种。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610811515.9A CN106420829A (zh) | 2016-09-08 | 2016-09-08 | 五谷虫制品用于制备治疗胶质细胞瘤的药品、保健品或食品中的应用 |
| PCT/CN2017/100684 WO2018045959A1 (zh) | 2016-09-08 | 2017-09-06 | 五谷虫制品用于制备治疗癌症的药品、保健品或食品中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610811515.9A CN106420829A (zh) | 2016-09-08 | 2016-09-08 | 五谷虫制品用于制备治疗胶质细胞瘤的药品、保健品或食品中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420829A true CN106420829A (zh) | 2017-02-22 |
Family
ID=58164350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610811515.9A Pending CN106420829A (zh) | 2016-09-08 | 2016-09-08 | 五谷虫制品用于制备治疗胶质细胞瘤的药品、保健品或食品中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420829A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018045959A1 (zh) * | 2016-09-08 | 2018-03-15 | 黄玉水 | 五谷虫制品用于制备治疗癌症的药品、保健品或食品中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991608A (zh) * | 2010-11-19 | 2011-03-30 | 浙江省医学科学院 | 蝇蛆提取物及其制备方法和用途 |
| CN103271947A (zh) * | 2013-06-06 | 2013-09-04 | 四川科伦新光生物科技开发有限公司 | 五谷虫抗肿瘤新用途 |
-
2016
- 2016-09-08 CN CN201610811515.9A patent/CN106420829A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991608A (zh) * | 2010-11-19 | 2011-03-30 | 浙江省医学科学院 | 蝇蛆提取物及其制备方法和用途 |
| CN103271947A (zh) * | 2013-06-06 | 2013-09-04 | 四川科伦新光生物科技开发有限公司 | 五谷虫抗肿瘤新用途 |
Non-Patent Citations (2)
| Title |
|---|
| 云贵: "水仙子昆虫蛋白研究概况", 《上海医药》 * |
| 华允芬等: "特种五谷虫脂肪酸的体外抗肿瘤、抗HIV-1整合酶活性及组成分析", 《昆虫学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018045959A1 (zh) * | 2016-09-08 | 2018-03-15 | 黄玉水 | 五谷虫制品用于制备治疗癌症的药品、保健品或食品中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106344615A (zh) | 五谷虫制品用于制备治疗非小细胞肺癌的药品、保健品或食品中的应用 | |
| CN106420827A (zh) | 五谷虫制品用于制备治疗结肠癌的药品、保健品或食品中的应用 | |
| CN107397208A (zh) | 以鱼鳔胶为主成分的功能食品及其用途 | |
| CN105664140A (zh) | 一种糖肽组合物及其制备方法和用途 | |
| CN106420829A (zh) | 五谷虫制品用于制备治疗胶质细胞瘤的药品、保健品或食品中的应用 | |
| CN102696910A (zh) | 用于预防治疗鸡传染性喉气管炎的饲料组合物和中药 | |
| CN104856980A (zh) | 四氢姜黄素的医药用途 | |
| CN105560608A (zh) | 一种治疗肺癌的药物组合物 | |
| CN104922268B (zh) | 一种从天然植物中提取活性物质的方法 | |
| CN107496473A (zh) | 黄秋葵水提取物在保护消化道功能中的应用 | |
| CN106265753A (zh) | 五谷虫制品用于制备治疗间质细胞瘤的药品、保健品或食品中的应用 | |
| Cui et al. | Antitumor effects of ethanol extracts from Hyptis rhomboidea in H22 tumor-bearing mice | |
| WO2018045959A1 (zh) | 五谷虫制品用于制备治疗癌症的药品、保健品或食品中的应用 | |
| CN108452240B (zh) | 一种抗肿瘤的中药组合物及其应用 | |
| Molefe | Anthelmintic, anticancer and phytochemical screening of Cotyledon orbiculata; Hermannia depressa; Nicotiana glauca and potassium permanganate | |
| Assis de Andrade et al. | A Review of the Popular Uses, Anatomical, Chemical, and Biological Aspects of Kalanchoe (Crassulaceae): A Genus of Plants Known as “Miracle Leaf” | |
| CN104784657A (zh) | 一种中兽药复方制剂在制备治疗鸡大肠杆菌病的药物中的应用 | |
| Phakoago | Geophagic practice and characterisation of plant remains in geophagic soils in Sekhukhune Area, Limpopo Province, South Africa | |
| CN109662970B (zh) | 一种羊毛甾烷型的应用 | |
| Wu et al. | Research Progress on the Medicinal and Edible Polygala fallax Hemsl.(Polygalaceae) Plant | |
| CN106924354B (zh) | 一种具有抑制肺癌细胞增殖作用的中药组合物及其应用 | |
| Rajbhoj et al. | A REVIEW ON HERBAL VETERINARY MEDICINAL PLANTS | |
| Sharma et al. | Therapeutic, Ethnomedicinal and Pharmacological Perspective of Bitter Apple Fruit (Citrullus Colocynthis (L.) Schrad | |
| CN103585303B (zh) | 一种治疗胃癌的药物组合物及其制备方法 | |
| CN105327061A (zh) | 一种治疗乳腺癌的中药及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |
|
| RJ01 | Rejection of invention patent application after publication |